secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001437749-24-025569
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Eton Q2 product sales up 40% YoY to $9.1M; ET-400 NDA accepted with Feb 2025 PDUFA
--------------------------------------------------------------------------------

- Product sales and royalty revenue $9.1M, up 40% YoY and 14% sequentially; 14th straight quarter of sequential growth.
- Net loss of $2.9M ($0.11/share) including $2.0M ET-400 filing fee; prior year net income $4.6M included $5.5M royalty sale.
- ALKINDI SPRINKLE revenue grew 63% YoY; Carglumic Acid sales continue to exceed expectations.
- NDA for ET-400 (hydrocortisone oral solution) accepted with PDUFA date Feb 28, 2025; launch quantities planned Q4 2024.
- Cash $17.7M; generated $1.3M operating cash flow in Q2; expects positive cash flow for remainder of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924025569/0001437749-24-025569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924025569/eton20240802_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-025569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer